Grant: Catalyst Grant: Pilot Projects in Aging
Université du Québec à Montréal
$31,190.00
Anatomo behavioral validation of the [18F]fluoroethoxybenzovesamicol, as a PET radiotracer for the diagnosis of Alzheimer disease.
FY 2009-10
Summary
The [18F] fluoroethoxybenzovesamicol (FEOBV) is a radioactive compound recently synthesized by our team at the Montreal Neurological Institute, in order to be used for brain imaging, using Positron emission tomography (PET). The FEOBV could be useful for the early diagnosis of AD, and for tracking the evolution of the diease. The compound is beleived to label specific cells known to be affected in AD, and associated with the symptoms. However, we still must directly demonstrate these two last points in animal before the first trial in human. This is the aim of the current pilot project. Anatomo-behavioral correlations will be searched by using FEOBV with PET imaging, behavioural tasks, and post mortem measures of cell death. Results will be used to request a "First in Human" trial to Health Canada. FEOBV has very high scientific, clinical and commercial potentials.
Department
Program
Catalyst Grant: Pilot Projects in Aging
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
191580
Name
Bedard Marc-André
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Aging
Theme2
Biomedical
Prcname2
Institute of Aging Pilot Projects
Projecttitle
Anatomo behavioral validation of the [18F]fluoroethoxybenzovesamicol, as a PET radiotracer for the diagnosis of Alzheimer disease.
Programtype2
Operating Grants
Orgnameinp2
Université du Québec à Montréal
Cihramount2
$31,190
Cihrequipment2
$18,810
Programname2
Catalyst Grant: Pilot Projects in Aging
Keyworddelim
Acetylcholine; Alzheimer; Animal Behavior; Biomarkers; Pet Imaging; Radiopharmaceutical Compound
Abstract
The [18F] fluoroethoxybenzovesamicol (FEOBV) is a radioactive compound recently synthesized by our team at the Montreal Neurological Institute, in order to be used for brain imaging, using Positron emission tomography (PET). The FEOBV could be useful for the early diagnosis of AD, and for tracking the evolution of the diease. The compound is beleived to label specific cells known to be affected in AD, and associated with the symptoms. However, we still must directly demonstrate these two last points in animal before the first trial in human. This is the aim of the current pilot project. Anatomo-behavioral correlations will be searched by using FEOBV with PET imaging, behavioural tasks, and post mortem measures of cell death. Results will be used to request a "First in Human" trial to Health Canada. FEOBV has very high scientific, clinical and commercial potentials.
Competitiondate
200909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bedard, Marc-André
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $31,190~ $18,810~